Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weight-adjusted low molecular weight heparin in recurrent implantation failure
2011-003080-30Phase 3Active
- Sponsor
- Humanitas Research Hospital
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of parnaparin in Recurrent Implantation Failure (RIF) and infertility (2 arms), sponsored by Humanitas Research Hospital. Primary endpoint: Pregnancy rate. Started Dec 2011; status: active.
02
Drugs
parnaparin
03
Conditions
Recurrent Implantation Failure (RIF)infertility
Beyond the preview
Go deeper on 2011-003080-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003080-30.